Bodenstedt Matthias 4

What Happened

• Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics (MLTX), sold a total of 87,795 shares in two open-market transactions: 85,870 shares on 2026-04-09 at a weighted average price of $18.94 (proceeds $1,626,378) and 1,925 shares on 2026-04-10 at a weighted average price of $19.51 (proceeds $37,557). Total proceeds were about $1.66 million. These were sales (not purchases).

Key Details

• Transaction dates and prices:
  • 2026-04-09: 85,870 shares sold, weighted avg price $18.94 (prices ranged $18.340–$19.455).
  • 2026-04-10: 1,925 shares sold, weighted avg price $19.51 (prices ranged $19.500–$19.560).
• Total shares sold: 87,795; total proceeds ≈ $1,663,935.
• Shares owned after transaction: Not disclosed in the information provided here (see the official Form 4 for post-transaction holdings).
• Notable footnotes:
  • The 4/9–4/10 sales were made pursuant to a Rule 10b5-1 trading plan adopted December 10, 2025 to cover the reporting person’s tax liabilities.
  • Reported prices are weighted averages; the filer noted multiple sale prices within the ranges above and will provide a full price breakdown if requested by the SEC, the issuer, or a security holder.
• Filing timeliness: Form 4 was filed on 2026-04-10 (appears timely relative to the transaction dates).

Context

• These sales were executed under a pre-established 10b5-1 trading plan to satisfy tax obligations; such planned sales are typically considered routine and do not necessarily signal the insider’s view on the company’s outlook. This report covers outright sales (transaction code S), not option exercises, gifts, or grants. For full details including remaining holdings, consult the official Form 4 filing (Accession: 0001213900-26-042629).